ORION PHARMA A/S: Financial statements 2025
CVR: 20601116
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ORION PHARMA A/S (CVR 20601116) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 329,561,856 and a net result of DKK 10,525,947 compared with DKK 10,899,639 the year before. That is an increase of 6.7% compared with the year before. The profit margin was 3.2%. Equity in the 2025 report amounted to DKK 32,510,625. The solvency ratio was 36.7%. The company had 14 employees in the financial year.
- Revenue
- DKK 329,561,856
- Gross Profit
- DKK 27,797,120
- Profit/Loss
- DKK 10,525,947
- Equity
- DKK 32,510,625
- Total Assets
- DKK 88,486,361
- Employees
- 14
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 329.6M | 27.8M | 10.5M | 32.5M | 14 |
| 2024 | 309M | 26.6M | 10.9M | 32M | 15 |
| 2023 | 253.1M | 25.1M | 8.2M | 51.7M | 16 |
| 2022 | 214.2M | 24.9M | 7.5M | 50.5M | 16 |
| 2021 | 212.5M | 20.7M | 4.5M | 47.9M | 17 |
Official annual report
How creditworthy is ORION PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ORION PHARMA A/S has won the tender "Amgros 2026 1.1482.b" issued by Amgros I/S worth 1,057,200,000 DKK.
ORION PHARMA A/S has won the tender "Amgros 2026 2.1390.b" issued by Amgros I/S worth 23,945,273 DKK.
ORION PHARMA A/S has won the tender "Amgros 2026 1.617.b" issued by Amgros I/S worth 43,827,250 DKK.
ORION PHARMA A/S has won the tender "Amgros 2026 2.212.a" issued by Amgros I/S worth 10,566,595 DKK.
ORION PHARMA A/S has won the tender "Amgros 2026 1.701.a" issued by Amgros I/S worth 1,428,533,153 DKK.
ORION PHARMA A/S has published its annual report for 2024. Revenue came to DKK 309,011,374, and the net result was DKK 10,899,639.
As of February 10, 2025, Mikko Tapani Kemppainen has joined the board of directors of ORION PHARMA A/S.
As of February 10, 2025, Satu Maarit Ahomäki has joined the board of directors of ORION PHARMA A/S.
As of February 10, 2025, Olli Heikki Huotari has left the board of directors of ORION PHARMA A/S.
As of February 9, 2025, Satu Maarit Ahomäki has left the board of directors of ORION PHARMA A/S.
About ORION PHARMA A/S
ORION PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1953. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ERCOPHARM A/S. The management consists of Jesper Otto Qvist-Pedersen. The board consists of Satu Maarit Ahomäki (chair), Mikko Tapani Kemppainen and René Kristian Lindell. The company is owned by Orion Corporation. The company has 14 employees (2026). In 2025, the company reported revenue of DKK 329,561,856 and a net result of DKK 10,525,947 compared with DKK 10,899,639 the year before. Equity in the 2025 report amounted to DKK 32,510,625.